Adriane Fugh-Berman, associate professor physiology and biophysics, on the need for higher penalties when drug companies market their products for unapproved uses:
"Drug companies will continue to market off-label unless the financial downside makes it unprofitable."
Off-Label Use Too Profitable to Stop
September 8, 2009, The Philadelphia Inquirer
(Please note that some news sites may require registration and/or some links may expire after 24 hours.)
